Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103598089 | 10359808 | 9 | F | 2013 | 20160824 | 20140804 | 20160828 | EXP | PHHY2014CA058372 | NOVARTIS | 57.91 | YR | M | Y | 0.00000 | 20160829 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103598089 | 10359808 | 1 | PS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, QMO (EVERY FOUR WEEKS) | U | 21008 | 30 | MG | /month |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 103598089 | 10359808 | 1 | Neuroendocrine tumour |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 103598089 | 10359808 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 103598089 | 10359808 | Bile duct obstruction | |
| 103598089 | 10359808 | Blood pressure increased | |
| 103598089 | 10359808 | Blood pressure systolic increased | |
| 103598089 | 10359808 | Heart rate decreased | |
| 103598089 | 10359808 | Liver disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 103598089 | 10359808 | 1 | 20130802 | 0 |